https://www.selleckchem.com/products/gossypol.html
ISTRATION EudraCT 2016-001110-19 (registered 2016-08-08).PURPOSE We analysed quantitative biomarkers derived from both baseline whole-body imaging and blood serum to identify prognostic markers in patients treated within the lutetium-177 prostate-specific membrane antigen (LuPSMA) phase 2 trial. METHODS PET image analysis was carried out using whole-body segmentation quantifying molecular tumour volume (SUV 3 threshold for PSMA, SUV liver+2sd for fluorodeoxyglucose (FDG) including SUVmax and SUVmean. For baseline bone scans,
إعجاب
علق
شارك
